Advertisement

Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies

Allan J. Paul DVM, MS1, Douglas E. Hutchens DVM, PhD2,3, Lawrence D. Firkins DVM, MS, MBA4, and Coleen M. Keehan DVM5,6
View More View Less
  • 1 Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.
  • | 2 Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.
  • | 3 Present address is Elanco Animal Health, Greenfield, IN 46140.
  • | 4 Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.
  • | 5 Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.
  • | 6 Present address is Village Animal Clinic, 25 W 510 Geneva Rd, Carol Stream, IL 60188.

Abstract

Objective—To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin- sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.

Animals—15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.

Procedure—Dogs were assigned to 3 treatment groups (control, 3×, or 5× group) in a randomized block design on the basis of the maximal ivermectinsensitivity score obtained during preliminary screening. Dogs in groups 3× and 5× were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.

Results—None of the dogs had clinical abnormalities during the study period.

Conclusions and Clinical Relevance—Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose. ( Am J Vet Res 2004;65:277–278)